Comments
Loading...
Spyre Therapeutics Analyst Ratings and Price Targets | NASDAQ:SYRE | Benzinga
Spyre Therapeutics Inc has a consensus price target of $47.67 based on the ratings of 12 analysts. The high is $65 issued by Baird on November 13, 2024. The low is $31 issued by Jefferies on December 11, 2023. The 3 most-recent analyst ratings were released by Leerink Partners, Baird, and Guggenheim on April 8, 2025, November 13, 2024, and October 25, 2024, respectively. With an average price target of $58.33 between Leerink Partners, Baird, and Guggenheim, there's an implied 214.47% upside for Spyre Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
Baird
Guggenheim
Wedbush
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Spyre Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/08/2025 | Buy Now | 142.59% | Leerink Partners | Faisal Khurshid43% | → $45 | Initiates | → Outperform | Get Alert |
| 12/11/2024 | Buy Now | — | Jones Trading | Debanjana Chatterjee45% | — | Initiates | → Hold | Get Alert |
| 11/13/2024 | Buy Now | 250.4% | Baird | Colleen Kusy36% | $50 → $65 | Maintains | Outperform | Get Alert |
| 10/25/2024 | Buy Now | 250.4% | Guggenheim | Yatin Suneja56% | $50 → $65 | Maintains | Buy | Get Alert |
| 09/04/2024 | Buy Now | 142.59% | Wedbush | David Nierengarten62% | → $45 | Initiates | → Outperform | Get Alert |
| 07/16/2024 | Buy Now | — | Evercore ISI Group | Umer Raffat43% | — | Initiates | → Outperform | Get Alert |
| 05/13/2024 | Buy Now | 115.63% | Wells Fargo | Yanan Zhu44% | $35 → $40 | Maintains | Overweight | Get Alert |
| 05/10/2024 | Buy Now | 115.63% | BTIG | Julian Harrison39% | $32 → $40 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | 169.54% | Baird | Colleen Kusy36% | → $50 | Initiates | → Outperform | Get Alert |
| 03/26/2024 | Buy Now | 191.11% | Stifel | Alex Thompson44% | $36 → $54 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 88.68% | Wells Fargo | Yanan Zhu44% | $12 → $35 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/20/2023 | Buy Now | 72.51% | BTIG | Julian Harrison39% | → $32 | Initiates | → Buy | Get Alert |
| 12/18/2023 | Buy Now | 45.55% | Stifel | Alex Thompson44% | $23 → $27 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | 137.2% | Guggenheim | — | → $44 | Initiates | → Buy | Get Alert |
| 12/11/2023 | Buy Now | 67.12% | Jefferies | Akash Tewari42% | → $31 | Initiates | → Buy | Get Alert |
| 11/29/2023 | Buy Now | — | TD Cowen | Tyler Van Buren44% | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Spyre Therapeutics (SYRE) stock?
The latest price target for Spyre Therapeutics (NASDAQ:SYRE) was reported by Leerink Partners on April 8, 2025. The analyst firm set a price target for $45.00 expecting SYRE to rise to within 12 months (a possible 142.59% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Spyre Therapeutics (SYRE)?
The latest analyst rating for Spyre Therapeutics (NASDAQ:SYRE) was provided by Leerink Partners, and Spyre Therapeutics initiated their outperform rating.
When was the last upgrade for Spyre Therapeutics (SYRE)?
The last upgrade for Spyre Therapeutics Inc happened on March 1, 2024 when Wells Fargo raised their price target to $35. Wells Fargo previously had an equal-weight for Spyre Therapeutics Inc.
When was the last downgrade for Spyre Therapeutics (SYRE)?
There is no last downgrade for Spyre Therapeutics.
When is the next analyst rating going to be posted or updated for Spyre Therapeutics (SYRE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spyre Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spyre Therapeutics was filed on April 8, 2025 so you should expect the next rating to be made available sometime around April 8, 2026.
Is the Analyst Rating Spyre Therapeutics (SYRE) correct?
While ratings are subjective and will change, the latest Spyre Therapeutics (SYRE) rating was a initiated with a price target of $0.00 to $45.00. The current price Spyre Therapeutics (SYRE) is trading at is $18.55, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
